Aclaris Therapeutics, Inc. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. The filing is an annual Form 10-K, not a standalone 2020 fourth-quarter filing. Aclaris is a clinical-stage biopharmaceutical company developing immuno-inflammatory therapies and pursuing partnerships for development, regulatory approval and commercialization.
Business Context and Pipeline
- Lead programs were ATI-450, an oral MK2 inhibitor in Phase 2 development for rheumatoid arthritis and other immuno-inflammatory diseases, and ATI-1777, a topical “soft” JAK 1/3 inhibitor in Phase 2a development for atopic dermatitis.
- ATI-2138, an oral ITK/TXK/JAK3 inhibitor for psoriasis and inflammatory bowel disease, was in preclinical development; an IND filing was expected in the second half of 2021.
- The company also supported an investigator-initiated Phase 2a COVID-19 trial of ATI-450 and expected data in the first half of 2021.
- Enrollment in the ATI-450 CAPS trial was paused because of COVID-19, and Aclaris redirected resources toward other immuno-inflammatory programs.
- Contract research services are provided through wholly owned subsidiary Aclaris Life Sciences. Aclaris has no manufacturing facilities and relies on third parties for clinical and preclinical supplies.
Financial Performance and Liquidity
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Total revenue | $6.5 million | $4.2 million | +$2.3 million |
| Contract research revenue | $5.8 million | $4.2 million | +$1.6 million |
| Other revenue | $0.7 million | — | +$0.7 million |
| Cost of revenue | $5.1 million | $4.1 million | +$1.1 million |
| Research and development | $31.7 million | $64.9 million | -$33.2 million |
| General and administrative | $20.5 million | $27.8 million | -$7.3 million |
| Loss from operations | $(50.9) million | $(111.1) million | Improved by $60.1 million |
| Net loss | $(51.0) million | $(161.4) million | Improved by $110.3 million |
| Basic and diluted loss per share | $(1.20) | $(3.90) | Improved by $2.70 |
| Operating cash flow | $(38.6) million | $(96.4) million | Improved by $57.8 million |
The filing does not present gross profit as a performance measure because management believes it is not meaningful at the company’s current revenue scale. On the reported figures, revenue remained substantially below operating expenses, and the company remained loss-making.
- Cash, cash equivalents and marketable securities totaled $54.1 million at December 31, 2020, consisting of $22.1 million of cash and cash equivalents and $32.1 million of marketable securities.
- Total assets were $70.8 million, total liabilities were $33.1 million and stockholders’ equity was $37.7 million at year-end.
- Long-term debt was $10.7 million net of issuance costs. The company borrowed $11.0 million from Silicon Valley Bank in March 2020 at an annual rate equal to the greater of prime plus 2% or 6.75%, with principal payments beginning in April 2022 and maturity in March 2024.
- Cash used in investing activities was $6.4 million, while financing activities provided $18.4 million, including $10.9 million of net debt proceeds and $7.7 million from equity sales to Lincoln Park.
- Stock-based compensation expense was $11.2 million in 2020, compared with $16.1 million in 2019.
- Accumulated deficit was $504.5 million at December 31, 2020. The company reported federal and state NOL carryforwards of $367.6 million and $369.6 million, respectively, subject to potential Section 382 limitations.
Material Changes Versus FY2019
- Revenue increased 53%, primarily from higher contract research revenue and $0.7 million of royalties on RHOFADE sales under the EPI Health agreement.
- Research and development expense declined 51% as 2019 included substantial spending on legacy JAK programs, A-101 clinical trials, licensing and milestone payments. ATI-450, ATI-1777 and ATI-2138 spending increased as those programs advanced.
- General and administrative expense decreased 26%, primarily because of lower headcount following the 2019 restructuring, lower stock-based compensation, reduced legal costs and lower travel.
- FY2019 included an $18.5 million goodwill impairment charge; no goodwill impairment was recorded in 2020.
- Discontinued operations shifted from a $47.8 million loss in 2019 to $0.1 million of income in 2020. The 2019 loss included a $27.6 million RHOFADE intangible-asset impairment charge and commercial operating costs.
- RHOFADE rights were sold to EPI Health in October 2019. The company discontinued ESKATA sales in August 2019 and is no longer operating a commercial product business.
- Employee headcount was 60 at December 31, 2020, including 57 full-time employees, following the 2019 restructuring.
Guidance, Outlook, Risks and Unusual Items
- Management expected to advance ATI-450 into a Phase 2b rheumatoid arthritis trial in the second half of 2021, obtain ATI-1777 data around mid-2021 and file an ATI-2138 IND in the second half of 2021.
- The company expected continuing losses and stated that additional capital would be required to complete development of ATI-450 and ATI-1777, advance preclinical programs and support discovery efforts.
- Management stated that year-end liquidity was expected to fund operating and capital requirements for more than 12 months from the financial statement issuance date, but this conclusion depends on current operating assumptions and development spending.
- In January 2021, after year-end, Aclaris raised $103.5 million of net proceeds through a public offering of 6.3 million common shares. This materially improved liquidity but diluted existing stockholders.
- COVID-19 disrupted clinical operations and supply-chain activities, including pausing CAPS enrollment. Additional delays, enrollment challenges, manufacturing disruptions and capital-market effects remained possible.
- Key risks include clinical failure, adverse safety findings, regulatory delays or rejection, dependence on third-party manufacturers and CROs, inability to secure strategic partners, competition from larger pharmaceutical companies, intellectual-property challenges and the need for additional financing.
- Contingent consideration related to the Confluence acquisition was $4.1 million at year-end, after a $2.4 million 2020 expense arising from updated assumptions following ATI-450 and ATI-1777 development progress. Remaining contingent consideration could reach $75.0 million, plus potential royalties and other payments.
- Material legal matters included a securities class action, a related derivative action and a product-liability lawsuit involving ESKATA. The company stated that it could not reasonably predict the outcome or potential loss for these matters.
Most Important Facts for Investors to Verify
- Verify the final data and regulatory status of ATI-450, ATI-1777 and ATI-2138, including whether the planned 2021 milestones occurred.
- Assess current cash burn and liquidity after the January 2021 equity offering, including dilution from the offering and the SVB warrant exercised in January 2021.
- Review the company’s dependence on future equity or debt financing and the assumptions supporting liquidity for more than 12 months.
- Evaluate the significance and valuation sensitivity of the $4.1 million contingent consideration liability and potential payments of up to $75.0 million.
- Monitor COVID-19 effects on trial enrollment, manufacturing, clinical timelines and regulatory interactions.
- Review the status, insurance coverage and potential exposure associated with the securities, derivative and ESKATA product-liability proceedings.
- Confirm royalty and milestone economics under the EPI Health and Confluence agreements, including potential future revenue and payment obligations.